Novel antagonists of the toll-like receptor 4
OwnerLeonardus Antonius B. JOOSTENinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel antagonist of the Toll-like receptor 4 (TLR-4). More specifically, the present invention relates to a lipopolysaccharide (LPS) isolated from the bacterium Bartonella quintana as a novel antagonist of the Toll-like receptor 4 (TLR-4). Further, the present invention relates to the use of said natural antagonist for the treatment of an autoimmune or inflammatory disease in a mammal and specifically for the treatment of rheumatoid arthritis (RA). Furthermore, the present invention relates to pharmaceutical compositions comprising a lipopolysaccharide (LPS) isolated from the bacterium Bartonella quintana.
Claims12
Use of Bartonella quintana lipopolysaccharide or a functional equivalent fragment thereof for the preparation of a medicament for the treatment of an autoimmune disease, an autoinflammatory disease, or an infectious disease in a mammal.
Bartonella quintana lipopolysaccharide or a functional equivalent fragment thereof for use as a medicament.
Medicament comprising Bartonella quintana lipopolysaccharide or a functional equivalent fragment thereof and one or more pharmaceutically acceptable excipients and/or carriers.
Method for treating an autoimmune or inflammatory disease comprising administering an therapeutic amount of Bartonella quintana lipopolysaccharide or a functional equivalent fragment thereof to a mammal suffering from an autoimmune, an autoinflammatory, or an infectious disease.
Use of a Toll-like 4 receptor (TLR-4) antagonist for the preparation of a medicament for the treatment of rheumatoid arthritis.
Dependencies are inferred from the claim text.